Circassia Pharmaceuticals PLC (CIR) Given Average Recommendation of “Buy” by Brokerages
Circassia Pharmaceuticals PLC (LON:CIR) has earned an average recommendation of “Buy” from the six research firms that are presently covering the stock. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is GBX 145 ($1.79).
A number of brokerages recently weighed in on CIR. Peel Hunt cut Circassia Pharmaceuticals PLC to an “add” rating and dropped their price target for the stock from GBX 509 ($6.30) to GBX 160 ($1.98) in a research note on Tuesday, June 21st. Royal Bank Of Canada cut Circassia Pharmaceuticals PLC to a “sector performer” rating and dropped their price target for the stock from GBX 430 ($5.32) to GBX 105 ($1.30) in a research note on Tuesday, June 21st. Stifel Nicolaus cut Circassia Pharmaceuticals PLC to a “hold” rating in a research note on Tuesday, June 21st. JPMorgan Chase & Co. dropped their price target on Circassia Pharmaceuticals PLC from GBX 410 ($5.07) to GBX 170 ($2.10) and set an “overweight” rating on the stock in a research note on Tuesday, June 21st. Finally, Barclays PLC began coverage on Circassia Pharmaceuticals PLC in a research report on Tuesday, June 21st. They set an “overweight” rating and a GBX 170 ($2.10) price objective for the company.
Shares of Circassia Pharmaceuticals PLC (LON:CIR) opened at 89.75 on Wednesday. The firm’s market cap is GBX 255.69 million. The firm has a 50-day moving average of GBX 93.90 and a 200 day moving average of GBX 166.77. Circassia Pharmaceuticals PLC has a 12 month low of GBX 81.05 and a 12 month high of GBX 322.90.
Circassia Pharmaceuticals PLC Company Profile
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Stock Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.